Protagonist Therapeutics Inc
PTGXHealthcare|Biotechnology|USA
$131.42
-6.22 (-4.52%)
DCF (FCF)
$3.72
Tangible Book
$10.21
About
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Stock Price
+148.8%(1Y)
Pipeline Summary
14 total trials5
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
Terminated: 1Completed: 10Active: 2Recruiting: 1
Active Trials (3)
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790Polycythemia Vera
Phase 3Active
Enrollment: 293 participants
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
NCT06033586Polycythemia Vera
Phase 3Active
Enrollment: 46 participants
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.
NCT07153146Healthy Volunteer
Phase 1Recruiting
Enrollment: 142 participants
BioScore
5.4/10
Watchlist
Ownership
Recent Insider Trades
Waddill William D.SELL
2026-06-239,000 shares @ $117.94
Waddill William D.SELL
2026-06-109,000 shares @ $107.68
Waddill William D.SELL
2026-05-299,000 shares @ $99.64
PATEL DINESH V PH DSELL
2026-05-1275,000 shares @ $100.12
Giraudo BryanSELL
2026-05-0859,130 shares @ $100.1
Recent News
2026-07-07 12:39:32
2026-06-17 22:00:11
Data last updated: Jul 12, 2026, 07:38 PM